Following the discovery of erythroblastic oncogene B2 (ERBB2) gene amplification in breast cancer, the human epidermal growth factor receptor 2 (HER2) has emerged as an attractive target for antibody therapies [3]. This evidence concerns the gene ERBB2 and breast carcinoma.